Stryker Co. (SYK) Shares Sold by OppenheimerFunds Inc.
OppenheimerFunds Inc. trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 50.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 965,727 shares of the medical technology company’s stock after selling 1,001,321 shares during the period. OppenheimerFunds Inc. owned approximately 0.26% of Stryker worth $163,072,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Kaizen Advisory LLC lifted its holdings in Stryker by 142.6% during the 2nd quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock valued at $127,000 after purchasing an additional 442 shares during the last quarter. CX Institutional bought a new position in Stryker during the 2nd quarter valued at about $133,000. NumerixS Investment Technologies Inc bought a new position in Stryker during the 2nd quarter valued at about $135,000. Bruderman Asset Management LLC bought a new position in Stryker during the 1st quarter valued at about $152,000. Finally, Ostrum Asset Management bought a new position in Stryker during the 1st quarter valued at about $160,000. 75.12% of the stock is owned by institutional investors.
In other news, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the completion of the sale, the vice president now owns 11,367 shares in the company, valued at approximately $1,896,470.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.40% of the stock is owned by insiders.
Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.03. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The company had revenue of $3.32 billion during the quarter, compared to the consensus estimate of $3.31 billion. During the same period in the previous year, the firm posted $1.53 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. equities research analysts anticipate that Stryker Co. will post 7.25 earnings per share for the current year.
Several brokerages recently issued reports on SYK. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $196.00 price target for the company in a report on Friday, June 1st. Citigroup lifted their price target on shares of Stryker from $171.00 to $173.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Sanford C. Bernstein began coverage on shares of Stryker in a report on Wednesday, June 27th. They set a “market perform” rating and a $177.00 price target for the company. Cantor Fitzgerald lifted their price target on shares of Stryker from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Finally, BTIG Research began coverage on shares of Stryker in a report on Thursday, August 16th. They set a “buy” rating and a $187.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $177.25.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Dividend
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.